Interim sustained virologic response (SVR), safety and tolerability results of 8-week treatment with ACH-3102 and sofosbuvir in chronic hepatitis C (HCV), genotype-1 (GT-1), treatment-naive patients: a Phase 2 "proxy" study

被引：0
|
作者：
Gane, Edward J. [1 ]
Kocinsky, Hetal [2 ]
Schwabe, Christian [3 ]
Mader, Michael [2 ]
Suri, Vithika [3 ]
Donohue, Mary K. [2 ]
Huang, Mingjun [2 ]
Hui, James [2 ]
Yang, Joanna [2 ]
Apelian, David [2 ]
机构：
[1] Auckland Hosp, New Zealand Liver Transplant Unit, Auckland, New Zealand
[2] Achill Pharmaceut, New Haven, CT USA
[3] Auckland Clin Studies Ltd, Grafton, New Zealand
来源：
HEPATOLOGY | 2014年 / 60卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
LB-23
引用
收藏
页码：1281A / 1282A
页数：2
相关论文
共 50 条
  • [31] Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response
    Howell, CD
    Jeffers, LS
    Cassidy, W
    Reddy, KR
    Hu, S
    Lee, JS
    JOURNAL OF VIRAL HEPATITIS, 2006, 13 (06) : 371 - 376
  • [32] SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAIVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL
    Jacobson, I.
    Dore, G. J.
    Foster, G. R.
    Fried, M. W.
    Radu, M.
    Rafalskiy, V. V.
    Moroz, L.
    Craxi, A.
    Peeters, M.
    Lenz, O.
    Ouwerkerk-Mahadevan, S.
    Kalmeijer, R.
    Beumont-Mauviel, M.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S574 - S574
  • [33] SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON α2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS
    Lawitz, Eric
    Rodriguez-Torres, Maribel
    Rustgi, Vinod K.
    Hassanein, Tarek
    Rahimy, Mohamad H.
    Crowley, Constance A.
    Freddo, James L.
    Muir, Andrew J.
    McHutchison, John G.
    HEPATOLOGY, 2010, 52 (04) : 334A - 335A
  • [34] Treatment Response and Tolerability to Pegylated Interferon (PEG Inf) and Ribavirin (RBV) in Treatment-Naive Asian American Patients with Chronic Hepatitis C and Genotype 1, 2/3 and 6
    Nguyen, Nghia H.
    Vutien, Philip
    Trinh, Huy N.
    Garcia, Ruel T.
    Wan, Kenton
    Nguyen, Huy A.
    Nguyen, Khanh K.
    Levitt, Brian S.
    Nguyen, Mindie H.
    GASTROENTEROLOGY, 2009, 136 (05) : A791 - A791
  • [35] Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
    Kowdley, Kris V.
    Lawitz, Eric
    Crespo, Israel
    Hassanein, Tarek
    Davis, Mitchell N.
    DeMicco, Michael
    Bernstein, David E.
    Afdhal, Nezam
    Vierling, John M.
    Gordon, Stuart C.
    Anderson, Jane K.
    Hyland, Robert H.
    Dvory-Sobol, Hadas
    An, Di
    Hindes, Robert G.
    Albanis, Efsevia
    Symonds, William T.
    Berrey, M. Michelle
    Nelson, David R.
    Jacobson, Ira M.
    LANCET, 2013, 381 (9883): : 2100 - 2107
  • [36] Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naive patients from India
    Behera, Manas Kumar
    Shukla, Sunit Kumar
    Dixit, Vinod Kumar
    Nath, Preetam
    Abhilash, V. B.
    Asati, Pankaj Kumar
    Jain, Ashok Kumar
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2018, 148 (02) : 200 - 206
  • [37] SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON α2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS
    Lawitz, E.
    Rodriquez-Torres, M.
    Rustgi, V. K.
    Hassanein, T.
    Rahimy, M. H.
    Crowley, C. A.
    Freddo, J. L.
    Muir, A.
    McHutchison, J.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S467 - S467
  • [38] A Phase III Study of the Safety and Efficacy of Viramidine Versus Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C: ViSER1 Results
    Benhamou, Yves
    Afdhal, Nezam H.
    Nelson, David R.
    Shiffman, Mitchell L.
    Halliman, Deanine G.
    Heise, Jamie
    Chun, Eric
    Pockros, Paul J.
    HEPATOLOGY, 2009, 50 (03) : 717 - 726
  • [39] HIGH SUSTAINED VIROLOGIC RESPONSE RATE IN TREATMENT-NAIVE HCV GENOTYPE 1A AND 1B PATIENTS TREATED FOR 12 WEEKS WITH AN INTERFERON-FREE ALL-ORAL QUAD REGIMEN: INTERIM RESULTS
    Sulkowski, M.
    Rodriguez-Torres, M.
    Lawitz, E.
    Shiffman, M.
    Pol, S.
    Herring, R.
    McHutchison, J.
    Pang, P.
    Brainard, D.
    Wyles, D.
    Habersetzer, F.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S560 - S560
  • [40] Sustained virologic response rates with albinterferon alfa-2b plus ribavirin treatment in ifini-naive, chronic hepatitis C genotype 1 patients
    Zeuzem, Stefan
    Yoshida, Eric M.
    Benhamov, Yves
    Bain, Vincent G.
    Shouval, Daniel
    Pianko, Stephen
    Flisiak, Robert
    Grigorescu, Mircea
    Rehak, Vratislav
    Kaita, Kelly D.
    Cronin, Patrick
    Pulkstenis, Erik
    Subramanian, G. M.
    McHutchison, John G.
    HEPATOLOGY, 2007, 46 (04) : 317A - 318A
12345